# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)

> **NCT03626662** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 79 (actual)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** AMG 890
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03626662
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-30
- **Primary completion:** 2023-04-18
- **Final completion:** 2023-04-18
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03626662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03626662, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03626662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*